

Matthias Brendel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6820317/publications.pdf>

Version: 2024-02-01

142
papers

4,509
citations

136950

32
h-index

138484

58
g-index

155
all docs

155
docs citations

155
times ranked

5324
citing authors

#	ARTICLE	IF	CITATIONS
1	Binding potential changes of SERT in patients with depression are associated with remission: A prospective [^{18}F]-CIT-SPECT study.. <i>Experimental and Clinical Psychopharmacology</i> , 2023, 31, 219-227.	1.8	2
2	Glitter in the Darkness? Nonfibrillar β -Amyloid Plaque Components Significantly Impact the β -Amyloid PET Signal in Mouse Models of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2022, 63, 117-124.	5.0	14
3	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster β -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 103-115.	0.8	24
4	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain ^{18}F -FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 563-584.	6.4	41
5	^{68}Ga -EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	6.4	15
6	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. <i>EMBO Journal</i> , 2022, 41, e109108.	7.8	38
7	Impact of Partial Volume Correction on [^{18}F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204.	2.3	2
8	Reduced Acquisition Time [^{18}F]GE-180 PET Scanning Protocol Replaces Gold-Standard Dynamic Acquisition in a Mouse Ischemic Stroke Model. <i>Frontiers in Medicine</i> , 2022, 9, 830020.	2.6	5
9	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. <i>Cancers</i> , 2022, 14, 53.	3.7	12
10	Detection of Splenic Tissue Using $^{99\text{m}}\text{Tc}$ -Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis. <i>Diagnostics</i> , 2022, 12, 486.	2.6	3
11	Longitudinal [^{18}F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. <i>Biomedicines</i> , 2022, 10, 738.	3.2	8
12	Detection of cardiac apoptosis by [^{18}F]ML-10 in a mouse model of permanent LAD ligation. <i>Molecular Imaging and Biology</i> , 2022, , 1.	2.6	2
13	Chronic PPAR β Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 854031.	3.4	5
14	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
15	Feasibility of [^{68}Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3571-3580.	6.4	12
16	Multicenter ^{18}F -PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 458.	4.0	9
17	EANM procedure guidelines for brain PET imaging using [^{18}F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651.	6.4	82
18	Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial ^{18}kDa translocator protein (TSPO). <i>Nature Neuroscience</i> , 2022, 25, 317-329.	14.8	29

#	ARTICLE	IF	CITATIONS
19	Longitudinal [¹⁸ UCB-H]/[¹⁸ F]FDG imaging depicts complex patterns of structural and functional neuroplasticity following bilateral vestibular loss in the rat. <i>Scientific Reports</i> , 2022, 12, 6049.	3.3	4
20	¹⁸ F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.262854.	5.0	8
21	Total Tumor Volume on ¹⁸ F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with ²²⁵ Ac-PSMA-I&T. <i>Biomedicines</i> , 2022, 10, 946.	3.2	6
22	Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2798-2811.	6.4	15
23	Single-Cell Radiotracer Allocation via Immunomagnetic Sorting to Disentangle PET Signals at Cellular Resolution. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1459-1462.	5.0	8
24	Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [¹⁸ F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2222-2234.	3.5	10
25	Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. <i>Molecular Neurodegeneration</i> , 2022, 17, .	10.8	26
26	Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel ⁶⁸ Ga-mCXCL12 PET tracer. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2965-2975.	2.1	6
27	In Vivo Assessment of Neuroinflammation in ⁴ Repeat Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	3.9	37
28	Imaging of Tau Pathology in Neurodegenerative Diseases: An Update. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 253-263.	4.6	29
29	Bilateral vestibulopathy causes selective deficits in recombining novel routes in real space. <i>Scientific Reports</i> , 2021, 11, 2695.	3.3	26
30	Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation. <i>Theranostics</i> , 2021, 11, 8964-8976.	10.0	12
31	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European DLB consortium project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1277-1286.	0.8	5
32	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	3.4	2
33	Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on ¹⁸ F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. <i>Diagnostics</i> , 2021, 11, 423.	2.6	1
34	TERT-Promoter Mutational Status in Glioblastoma " Is There an Association With Amino Acid Uptake on Dynamic ¹⁸ F-FET PET?. <i>Frontiers in Oncology</i> , 2021, 11, 645316.	2.8	4
35	Microglial activation in the right amygdala-entorhinal-hippocampal complex is associated with preserved spatial learning in App mice. <i>NeuroImage</i> , 2021, 230, 117707.	4.2	16
36	Dosimetry and optimal scan time of [¹⁸ F]SiTATE-PET/CT in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3571-3581.	6.4	15

#	ARTICLE	IF	CITATIONS
37	White matter aging drives microglial diversity. <i>Neuron</i> , 2021, 109, 1100-1117.e10.	8.1	208
38	Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115.	3.9	46
39	Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
40	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	6.4	22
41	Dual-Phase ¹²⁵ I-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	3.4	13
42	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	2.4	11
43	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 663631.	2.8	7
44	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 3825.	12.8	29
45	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. <i>Cancers</i> , 2021, 13, 3163.	3.7	5
46	Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 103, 147.e1-147.e5.	3.1	4
47	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036.	6.4	6
48	Metabolic connectivity-based single subject classification by multi-regional linear approximation in the rat. <i>NeuroImage</i> , 2021, 235, 118007.	4.2	3
49	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
50	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 137.	6.2	59
51	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	2.7	13
52	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	12.4	108
53	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 774017.	2.8	10
54	Regional Associations of Cortical Superficial Siderosis and ¹²⁵ I-Amyloid-Positron-Emission-Tomography Positivity in Patients With Cerebral Amyloid Angiopathy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 786143.	3.4	0

#	ARTICLE	IF	CITATIONS
55	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster A β -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	3
56	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
57	Glitter in the darkness? Non-fibrillar A β -amyloid plaque components significantly impact the A β -amyloid PET signal. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
58	In vivo Braak staging using ¹⁸ F-Flortaucipir-tau PET as a predictive marker for future cognitive decline in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
59	Klotho's heterozygosity modifies amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e051343.	0.8	0
60	Feasibility of short imaging protocols for [¹⁸ F]PI-2620 tau PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
61	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
62	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. <i>Neurology</i> , 2020, 94, e861-e873.	1.1	24
63	Laquinimod ameliorates secondary brain inflammation. <i>Neurobiology of Disease</i> , 2020, 134, 104675.	4.4	11
64	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	3.9	42
65	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. <i>Journal of Neuroinflammation</i> , 2020, 17, 208.	7.2	19
66	Colocalization of Tau but Not A β -Amyloid with Cortical Superficial Siderosis in a Case with Probable CAA. <i>Case Reports in Neurology</i> , 2020, 12, 232-237.	0.7	4
67	Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. <i>EMBO Molecular Medicine</i> , 2020, 12, e12308.	6.9	73
68	FDG PET Data is Associated with Cognitive Performance in Patients from a Memory Clinic. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 207-216.	2.6	4
69	Assessment of ¹⁸ F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
70	Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. <i>Journal of Neuroinflammation</i> , 2020, 17, 374.	7.2	28
71	Asymmetry of plaque burden in amyloid mouse models. <i>Alzheimer's and Dementia</i> , 2020, 16, e039153.	0.8	0
72	Microglial activation in vivo is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039574.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Higher TREM2 levels and microglia activation associated with slower rates of amyloid PET increase in humans and a transgenic mouse model of beta-amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e039813.	0.8	0
74	18 F-PI-2620 tau-PET in corticobasal syndrome (ActiGliA cohort). <i>Alzheimer's and Dementia</i> , 2020, 16, e041469.	0.8	1
75	Microglial activation and brain networks in Alzheimer's disease: The ActiGliA cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043265.	0.8	0
76	Neuropathological characteristics associated with a recently identified rare PSEN1 deletion mutation (F175del). <i>Alzheimer's and Dementia</i> , 2020, 16, e045048.	0.8	0
77	Clinical, ocular motor, and imaging profile of Niemann-Pick type C heterozygosity. <i>Neurology</i> , 2020, 94, e1702-e1715.	1.1	18
78	Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1825-1831.	5.0	19
79	Direct comparison of activation maps during galvanic vestibular stimulation: A hybrid H2[15 O] PET-BOLD MRI activation study. <i>PLoS ONE</i> , 2020, 15, e0233262.	2.5	8
80	Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer's Disease Patients With Cognition and Glucose Metabolism. <i>Frontiers in Neuroscience</i> , 2020, 14, 604.	2.8	27
81	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
82	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	3.4	38
83	Loss of TMEM106B potentiates lysosomal and FTD-like pathology in progranulin-deficient mice. <i>EMBO Reports</i> , 2020, 21, e50241.	4.5	37
84	[18F]MPPF and [18F]FDG PET imaging in rats: impact of transport and restraint stress. <i>EJNMMI Research</i> , 2020, 10, 112.	2.5	6
85	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	2.7	14
86	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 67.	6.2	28
87	Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid- β^2 Mouse Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1787-1793.	5.0	41
88	Stereological Investigation of Regional Brain Volumes after Acute and Chronic Cuprizone-Induced Demyelination. <i>Cells</i> , 2019, 8, 1024.	4.1	6
89	PET Imaging of Astroglialosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 249.	3.4	30
90	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid- β^2 processing effects. <i>Neurobiology of Aging</i> , 2019, 84, 241.e5-241.e11.	3.1	9

#	ARTICLE	IF	CITATIONS
91	Expression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models. <i>Cells</i> , 2019, 8, 94.	4.1	32
92	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	5.7	141
93	Opposite microglial activation stages upon loss of <scp>PGRN</scp> or <scp>TREM</scp> 2 result in reduced cerebral glucose metabolism. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	87
94	In response to: The validity of 18F-GE180 as a TSPO imaging agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1208-1211.	6.4	19
95	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	5.3	47
96	Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, 923-924.	1.3	2
97	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. <i>Nature Neuroscience</i> , 2019, 22, 191-204.	14.8	358
98	Early and Longitudinal Microglial Activation but Not Amyloid Accumulation Predicts Cognitive Outcome in PS2APP Mice. <i>Journal of Nuclear Medicine</i> , 2019, 60, 548-554.	5.0	36
99	ICâ€Pâ€161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	3
100	Noradrenaline transporter availability on [11C]MRB PET predicts weight loss success in highly obese adults. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1618-1625.	6.4	7
101	Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification. <i>NeuroImage</i> , 2018, 165, 83-91.	4.2	27
102	Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo 1/4PET-study. <i>Journal of Neuroinflammation</i> , 2018, 15, 307.	7.2	40
103	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional AÎ² deposition rate and plaque burden at treatment initiation. <i>Theranostics</i> , 2018, 8, 4957-4968.	10.0	22
104	Imaging biomarkers of behavioral impairments: A pilot microâ€positron emission tomographic study in a rat electrical postâ€status epilepticus model. <i>Epilepsia</i> , 2018, 59, 2194-2205.	5.1	13
105	IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. <i>Neurology</i> , 2018, 91, 180-182.	1.1	23
106	Imaging correlates of behavioral impairments: An experimental PET study in the rat pilocarpine epilepsy model. <i>Neurobiology of Disease</i> , 2018, 118, 9-21.	4.4	23
107	Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimerâ€™s Disease Patients with Depressive Symptoms. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 793-806.	2.6	23
108	A novel real-space navigation paradigm reveals age- and gender-dependent changes of navigational strategies and hippocampal activation. <i>Journal of Neurology</i> , 2018, 265, 113-126.	3.6	11

#	ARTICLE	IF	CITATIONS
109	Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 174.	3.4	17
110	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	2.4	21
111	Rate of β -amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 1387-1396.	0.8	16
112	The correlation between striatal and cortical binding ratio of 11C-PiB-PET in amyloid-uptake-positive patients. <i>Annals of Nuclear Medicine</i> , 2018, 32, 398-403.	2.2	5
113	Data on specificity of [18F]GE180 uptake for TSPO expression in rodent brain and myocardium. <i>Data in Brief</i> , 2018, 19, 331-336.	1.0	4
114	Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. <i>NeuroImage: Clinical</i> , 2017, 14, 77-86.	2.7	91
115	The <i>FTD-like</i> syndrome causing <i>TREM2</i> T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. <i>EMBO Journal</i> , 2017, 36, 1837-1853.	7.8	152
116	Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1364-1374.	6.4	22
117	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248.	6.4	15
118	Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1984-1990.	5.0	37
119	Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?. <i>EJNMMI Research</i> , 2017, 7, 48.	2.5	76
120	Predicting Regional Pattern of Longitudinal β -Amyloid Accumulation by Baseline PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 639-645.	5.0	17
121	[18F]FDG PET accurately differentiates infected and non-infected non-unions after fracture fixation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 432-440.	6.4	20
122	Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. <i>Journal of Neuroimaging</i> , 2017, 27, 255-261.	2.0	23
123	TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. <i>EJNMMI Research</i> , 2017, 7, 89.	2.5	55
124	Increase of <i>TREM2</i> during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 8.	3.4	60
125	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. <i>Frontiers in Neurology</i> , 2017, 8, 665.	2.4	15
126	Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 109-113.	2.2	8

#	ARTICLE	IF	CITATIONS
127	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440.	3.4	58
128	Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [18F]-Florbetaben PET Quantitation in Alzheimer's Model Mice. <i>Frontiers in Neuroscience</i> , 2016, 10, 45.	2.8	42
129	Monitoring of Tumor Growth with [18F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches. <i>Frontiers in Neuroscience</i> , 2016, 10, 260.	2.8	13
130	¹⁸F-TREM-2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	6.9	392
131	Applied multimodal diagnostics in a case of presenile dementia. <i>BMC Neurology</i> , 2016, 16, 131.	1.8	3
132	Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. <i>Stroke</i> , 2016, 47, 2645-2648.	2.0	29
133	Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?. <i>Radiation Oncology</i> , 2016, 11, 139.	2.7	59
134	Small-Animal PET Imaging of Tau Pathology with ¹⁸ F-THK5117 in 2 Transgenic Mouse Models. <i>Journal of Nuclear Medicine</i> , 2016, 57, 792-798.	5.0	35
135	Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 954-960.	5.0	113
136	P2-146: Temporo-parietal hypometabolism is associated with reduced functional connectivity of the default mode network in prodromal Alzheimer's disease. , 2015, 11, P542-P542.		0
137	Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 716-724.	6.4	67
138	Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. <i>NeuroImage</i> , 2015, 108, 450-459.	4.2	120
139	Mapping 3-year changes in gray matter and metabolism in A β -positive nondemented subjects. <i>Neurobiology of Aging</i> , 2015, 36, 2913-2924.	3.1	23
140	Cross-Sectional Comparison of Small Animal [18F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models. <i>PLoS ONE</i> , 2015, 10, e0116678.	2.5	45
141	Impact of partial volume effect correction on cerebral β -amyloid imaging in APP-Swe mice using [18F]-florbetaben PET. <i>NeuroImage</i> , 2014, 84, 843-853.	4.2	24
142	Longitudinal Assessment of Cerebral β -Amyloid Deposition in Mice Overexpressing Swedish Mutant β -Amyloid Precursor Protein Using ¹⁸ F-Florbetaben PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1127-1134.	5.0	75